SANDRA KELLEY: Open Payments
NPI 1699731679 · COLUMBUS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$288 in 14 payments from 8 companies in 2025. Trend: 2023 $563 · 2024 $633 · 2025 $288
Food & beverage: $288
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 3 | $53 |
| Biogen, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $44 |
| Exeltis, USA Inc. | 2 | $43 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| Celgene Corporation | 1 | $25 |
| Boston Scientific Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: ZURZUVAE, Veozah, SLYND, MYFEMBREE, REBLOZYL, Axonics, Lynkuet, GEMTESA.
Industry payments across GA — which companies pay providers there.
